Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Vincelette on MYC Expression in Myelofibrosis

January 20th 2024

Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.

MAJIC-PV: Clinical Implications in PV

January 19th 2024

Experts discuss the clinical implications of the MAJIC-PV trial.

Polycythemia Vera: Choosing the Right Treatment

January 19th 2024

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Frontline Tamibarotene Plus Venetoclax and Azacitidine Induces 100% CR Rate in SELECT-AML-1 Trial

January 16th 2024

Tamibarotene plus venetoclax/azacitidine elicited higher responses rates vs venetoclax/azacitidine in RARA-overexpressed acute myeloid leukemia.

GB2064 Displays Preliminary Efficacy, Tolerability in Myelofibrosis

January 16th 2024

GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.

Polycythemia Vera: Treatment Goals and Options

January 12th 2024

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

REVEAL Study: Clinical Implications

January 12th 2024

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Polycythemia Vera: Assessing Risk and Genetic Testing

January 12th 2024

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Dr Mascarenhas on the Potential Utility of Selinexor Plus Ruxolitinib in Myelofibrosis

January 11th 2024

John Mascarenhas, MD, discusses the potential advantages of utilizing selinexor with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Dr Kuykendall on the Efficacy of Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

January 9th 2024

Andrew Kuykendall, MD, discusses the efficacy of pelabresib plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Research Developments Provide Clarity and Raise Further Questions in Myeloma, Myelofibrosis, DLBCL, and MDS

January 5th 2024

Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.

Dr Sallman on the Rationale For Investigating Fedratinib in MDS/MPN Overlap Syndromes

January 4th 2024

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

Diagnosing Polycythemia Vera (PV)

December 19th 2023

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

TP-3654 Demonstrates Favorable Tolerability, Early Clinical Activity in R/R Myelofibrosis

December 19th 2023

The oral selective PIM1 kinase inhibitor TP-3654 appeared to be well tolerated and to show early signals of spleen volume reduction, symptom improvement, and correlating cytokine reductions in patients with relapsed or refractory myelofibrosis, according to preliminary data.

SRSF2 Mutations Lead to Lessened Frequency of Polycythemia in Preclinical MPN Models

December 13th 2023

The presence of mutated SRSF2 in knock-in mouse models of JAK2 V617F–driven myeloproliferative neoplasms reduced the rate of polycythemia and hampered hematopoietic progenitor functions.

Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo

December 13th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr Rampal on Findings From the MANIFEST-2 Trial in JAK Inhibitor–Naive Myelofibrosis

December 12th 2023

Raajit K. Rampal, MD, PhD, discusses findings from the phase 3 MANIFEST-2 trial investigating pelabresib in combination with ruxolitinib for JAK inhibitor–naive patients with myelofibrosis.

Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis

December 11th 2023

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

December 10th 2023

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

December 10th 2023

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.